Grazia Aleppo, United States of America

Northwestern University Feinberg School of Medicine
Grazia Aleppo, MD, FACE, FACP, Professor of Medicine Director, Diabetes Education Program, Associate Chief for Clinical Affairs Division of Endocrinology Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University (USA) Dr. Grazia Aleppo graduated magna cum laude from the University of Catania School of Medicine, Catania, Italy; subesquently completed internship, residency and endocrinology fellowship at The University of Illinois At Chicago. She is a professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at the Feinberg School of Medicine, Northwestern Uniersity, Chicago. She is also the Associate Chief for Clinical Affairs in the same Division and the Medical Director of the Northwestern Medicine Diabetes Training and Education Program. Dr Aleppo’s clinical interest and research interest is in Diabetes, particularly in the implementation of Diabetes Technology such as Insulin pump therapy, Continuous Glucose Monitoring (CGM) therapy and automated insulin delivery (AID) in clinical practice. She has participated in the major clinical trials on the use of CGM in various populations and was the protocol chair for the Replace-BG clinical trial which lead to the approval of CGM therapy for Medicare beneficiaries in the USA. She has been very active in scholarly activities with over 50 publications and book chapters in peer reviewed journals. She is a fellow of the American College of Endocrinology and the American College of Physicians and a member of many professional societies, including the American Diabetes Association, The Endocrine Society, the American Association of Clinical Endocrinologists, and the American College of Physicians. She is the Associate Editor of Diabetes Technology and Therapeutic journal and serves on the editorial board of BMJ Open Diabetes and Research Care. Dr Aleppo is considered a prominent national key opinion leader in the field of Diabetes Technology, including insulin pumps, CGM systems and automated insulin delivery.

Presenter of 3 Presentations

ORAL PRESENTATION SESSION

GLYCEMIC IMPROVEMENT IN 1,311 PATIENTS WITH TYPE 1 DIABETES (T1D) USING THE OMNIPOD DASH® INSULIN MANAGEMENT SYSTEM OVER FIRST 90 DAYS OF USE

Abstract

Background and Aims

Clinical outcomes describing real-world use of various devices by people with T1D are important to support decision-making. This retrospective study characterized patient-reported clinical outcomes of people with T1D in the United States before (baseline) and 90 days after (follow-up) initiation of the tubeless Omnipod DASH® Insulin Management System.

Methods

The primary outcome was change in self-reported HbA1c levels from baseline to follow-up. Secondary outcomes were change in self-reported total daily dose (TDD) of insulin and self-reported frequency of hypoglycemic events (HE) per week (#/week <70 mg/dL). Outcomes were assessed overall, by prior treatment modality (MDI or CSII), and by age (<18y, ≥18y).

Results

Patients (n=1,311) were divided into 2 age groups (<18y: n=405, ≥18y: n=906) aged 9.9±4.2y and 45.9±16.9y (mean±SD) and 49.6% and 60.7% female, respectively (Table 1). The overall change in self-reported HbA1c at follow-up was -0.9±2.0% for patients <18y (p<0.0001) and -0.8±1.4% for patients ≥18y (p<0.0001). The change in HbA1c for prior MDI and prior CSII users was ‑1.0±2.1% (p<0.0001) and -0.4±1.3% (p>0.05) in patients <18y, and -0.9±1.6% (p<0.0001) and -0.5±1.0% in patients ≥18y (p<0.0001), respectively. Overall change in TDD of insulin for patients <18y and ≥18y was ‑1.7±10.9U/d (p>0.05) and -12.8±27.7U/d (p<0.0001) and the self-reported HE frequency decreased significantly by -1.4±2.9 (p<0.0001) and -1.9±3.2 (p<0.0001) episodes per week, respectively.

Conclusions

This large cohort of patients with T1D using the Omnipod DASH® Insulin Management System exhibited significant reductions in HbA1c, TDD of insulin, and number of HE after 90 days of use across both age groups.

pro dash t1d 150ppi.png

Hide
INDUSTRY SESSION

Assessment of Glycaemic Outcomes with the Omnipod DASH™ System in the Adult population

INDUSTRY SESSION

rtCGM in the Type 2 Non-Intensive and Non-Insulin Population:  Review of Evidence and Clinical Practice